Drug Profile


Alternative Names: Ebrocit; FI 3542

Latest Information Update: 10 Nov 1998

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ferrer
  • Developer Ferrer; Robert
  • Class Antiulcers; Benzenesulfonates; Gastric antisecretories; Small molecules; Thiazoles
  • Mechanism of Action Histamine H2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Market Withdrawal Duodenal ulcer; Gastric ulcer
  • Discontinued Reflux oesophagitis

Most Recent Events

  • 10 Nov 1998 Discontinued-III for Reflux oesophagitis in Poland (PO)
  • 10 Nov 1998 Withdrawn for Duodenal ulcer in Peru (PO)
  • 10 Nov 1998 Withdrawn for Gastric ulcer in Peru (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top